Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Status: | Recruiting |
---|---|
Conditions: | Prostate Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 10/20/2018 |
Start Date: | February 8, 2018 |
End Date: | April 1, 2025 |
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy,
with or without cabazitaxel and prednisone, work in treating patients with
castration-resistant prostate cancer previously treated with docetaxel that has spread to
other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone
therapy using abiraterone acetate and antiandrogen therapy may fight prostate cancer by
lowering and/or blocking the use of androgens by the tumor cells. Drugs used in chemotherapy,
such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving abiraterone acetate and antiandrogen therapy with or without cabazitaxel
and prednisone may help kill more tumor cells.
with or without cabazitaxel and prednisone, work in treating patients with
castration-resistant prostate cancer previously treated with docetaxel that has spread to
other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone
therapy using abiraterone acetate and antiandrogen therapy may fight prostate cancer by
lowering and/or blocking the use of androgens by the tumor cells. Drugs used in chemotherapy,
such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving abiraterone acetate and antiandrogen therapy with or without cabazitaxel
and prednisone may help kill more tumor cells.
PRIMARY OBJECTIVES:
I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in
patients with castration-resistant prostate cancer (CRPC) that have previously received
docetaxel and androgen deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC)
can improve progression-free survival (PFS) compared to abiraterone acetate alone.
SECONDARY OBJECTIVES:
I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in
patients with CRPC that have previously received docetaxel and ADT for HSPC can increase the
percentage of change in prostate-specific antigen (PSA) from baseline to week 12 of treatment
as well as the maximum decline in PSA that occurs at any point after treatment compared to
abiraterone acetate alone.
II. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in
patients with CRPC that have previously received docetaxel for HSPC can prolong time to PSA
progression compared to abiraterone acetate alone.
III. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in
patients with CRPC that have previously received docetaxel for HSPC can improve radiographic
response (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) compared to
abiraterone acetate alone.
IV. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in
patients with CRPC that have previously received docetaxel and ADT for HSPC can prolong the
overall survival (OS) compared to abiraterone acetate alone.
V. To assess safety and tolerability of the combination of 6 cycles of cabazitaxel and
abiraterone acetate.
TERTIARY OBJECTIVES:
I. To examine whether patients with circulating tumor cells (CTCs) positive for AR-V7 at
baseline have a longer radiographic or clinical PFS to the combination of cabazitaxel and
abiraterone acetate vs. abiraterone acetate alone.
II. To examine whether the addition of cabazitaxel to abiraterone acetate can change the
AR-V7 status of patients who are positive at study entry.
III. To examine whether the addition of cabazitaxel to abiraterone acetate has any impact on
future development of AR-V7 positivity at the time of disease progression.
IV. To assess if the changes in total tumor burden from baseline to week 12 as assessed with
sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT) will differ
between two arms.
V. To correlate total tumor burden at the baseline as assessed with NaF PET/CT with the PFS.
VI. To correlate heterogeneity of response from baseline to week 12 as assessed with NaF
PET/CT with the PFS.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive abiraterone acetate orally (PO) once daily (QD) on days 1-21,
prednisone PO twice daily (BID) on days 1-21. Courses of abiraterone acetate and prednisone
repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients
receive cabazitaxel intravenously (IV) over 1 hour on day 1, and treatment with cabazitaxel
repeats every 21 days for up to 6 courses in the absence of disease progression or
unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with
either luteinizing hormone-releasing hormone (LHRH) agonist or antagonist, or surgical
castration with bilateral orchiectomy.
ARM B: Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive
standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical
castration with bilateral orchiectomy.
After completion of study treatment, patients are followed up every 3 or 6 months and then
annually for up to 5 years.
I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in
patients with castration-resistant prostate cancer (CRPC) that have previously received
docetaxel and androgen deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC)
can improve progression-free survival (PFS) compared to abiraterone acetate alone.
SECONDARY OBJECTIVES:
I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in
patients with CRPC that have previously received docetaxel and ADT for HSPC can increase the
percentage of change in prostate-specific antigen (PSA) from baseline to week 12 of treatment
as well as the maximum decline in PSA that occurs at any point after treatment compared to
abiraterone acetate alone.
II. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in
patients with CRPC that have previously received docetaxel for HSPC can prolong time to PSA
progression compared to abiraterone acetate alone.
III. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in
patients with CRPC that have previously received docetaxel for HSPC can improve radiographic
response (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) compared to
abiraterone acetate alone.
IV. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in
patients with CRPC that have previously received docetaxel and ADT for HSPC can prolong the
overall survival (OS) compared to abiraterone acetate alone.
V. To assess safety and tolerability of the combination of 6 cycles of cabazitaxel and
abiraterone acetate.
TERTIARY OBJECTIVES:
I. To examine whether patients with circulating tumor cells (CTCs) positive for AR-V7 at
baseline have a longer radiographic or clinical PFS to the combination of cabazitaxel and
abiraterone acetate vs. abiraterone acetate alone.
II. To examine whether the addition of cabazitaxel to abiraterone acetate can change the
AR-V7 status of patients who are positive at study entry.
III. To examine whether the addition of cabazitaxel to abiraterone acetate has any impact on
future development of AR-V7 positivity at the time of disease progression.
IV. To assess if the changes in total tumor burden from baseline to week 12 as assessed with
sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT) will differ
between two arms.
V. To correlate total tumor burden at the baseline as assessed with NaF PET/CT with the PFS.
VI. To correlate heterogeneity of response from baseline to week 12 as assessed with NaF
PET/CT with the PFS.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive abiraterone acetate orally (PO) once daily (QD) on days 1-21,
prednisone PO twice daily (BID) on days 1-21. Courses of abiraterone acetate and prednisone
repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients
receive cabazitaxel intravenously (IV) over 1 hour on day 1, and treatment with cabazitaxel
repeats every 21 days for up to 6 courses in the absence of disease progression or
unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with
either luteinizing hormone-releasing hormone (LHRH) agonist or antagonist, or surgical
castration with bilateral orchiectomy.
ARM B: Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive
standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical
castration with bilateral orchiectomy.
After completion of study treatment, patients are followed up every 3 or 6 months and then
annually for up to 5 years.
Inclusion Criteria:
- Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)
- Previous chemotherapy with at least 3 cycles of docetaxel for hormone-sensitive
metastatic prostate cancer
- Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases
on imaging studies (CT/magnetic resonance imaging [MRI] of abdomen/pelvis, bone
scintigraphy or NaF PET/CT)
- Ability to swallow abiraterone acetate tablets as a whole
- All patients must be receiving standard of care androgen deprivation treatment
(surgical castration versus LHRH agonist or antagonist treatment); subjects receiving
LHRH agonist or antagonist must continue treatment throughout the time on this study
- Patients must have castrate serum level of testosterone of < 50 ng/dL (< 1.73 nmol/L)
- Patients must have progressive disease while receiving androgen deprivation therapy
defined by any one of the following as per the Prostate Cancer Clinical Trials Working
Group 3 (PCWG3) criteria for PSA, measurable disease or non-measurable (bone) disease
during treatment with ADT:
- PSA: At least two consecutive rises in serum PSA, obtained at a minimum of 1-week
intervals, with the final value >= 2.0 ng/mL
- Measurable disease (by RECIST 1.1): > 20% increase in the sum of the longest
diameters of all measurable lesions or the development of new measurable lesions;
the short axis of a target lymph node must be more that 15 mm to be assessed for
change in size
- Non-measurable (bone) disease: The appearance of two or more new areas of uptake
on bone scan (or NaF PET/CT) consistent with metastatic disease compared to
previous imaging during castration therapy; the increased uptake of pre-existing
lesions on bone scan will not be taken to constitute progression, and ambiguous
results must be confirmed by other imaging modalities (e.g. X-ray, CT or MRI)
- Patients may or may not have been treated previously with a nonsteroidal antiandrogen,
such as flutamide, bicalutamide or nilutamide; for patients previously treated with an
antiandrogen, they must be off treatment for at least 4 weeks (for flutamide) or 6
weeks (for bicalutamide or nilutamide) prior to registration and must have shown PSA
progression after discontinuing the anti-androgen
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
0, 1, or 2
- Absolute neutrophil count (ANC) >= 1500/mm^3
- Hemoglobin (HgB) >= 9.0 gr/dL
- Platelets >= 100,000/mm^3
- Creatinine < 2.0 mg/dL
- Patients must be informed of the experimental nature of the study and its potential
risks, and must sign an Institutional Review Board (IRB)-approved written informed
consent form indicating such an understanding
- Patients with resected or irradiated brain metastases or those treated with
stereotactic radiation therapy are eligible to enroll, provided that they do not
require treatment with steroids that exceeds 10 mg of prednisone daily or equivalent
- Sexually active males must use an accepted and effective method of double barrier
contraception or abstain from sexual intercourse for the duration of their
participation in the study and for 26 weeks after the last dose of study drug
- NaF PET/CT OPTIONAL SUB-STUDY ELIGIBILITY CRITERIA
- Ability to lie still for imaging
- Weight =< 300 lbs (pounds)
Exclusion Criteria:
- Any prior chemotherapy or androgen receptor (AR)-directed therapy for CRPC, (e.g.
docetaxel, cabazitaxel, mitoxantrone, abiraterone acetate, ketoconazole, or
enzalutamide); previous treatment with radium-223 or sipuleucel-T is allowed
- Pure small cell or other variant (non-adenocarcinoma) prostate cancer histology for
which treatment with abiraterone would not be considered appropriate
- Patients may not be receiving other therapeutic investigational agents or be receiving
concurrent anticancer therapy other than standard androgen deprivation therapy;
concurrent treatment with agents to prevent skeletal-related events (such as
zoledronic acid or denosumab) will be allowed as long as it was initiated prior to
study entry
- Any medical condition for which prednisone (corticosteroid) is contraindicated
- If total bilirubin is > upper limit of normal (ULN) (NOTE: in subjects with Gilbert?s
syndrome, if total bilirubin is
> ULN, measure direct and indirect bilirubin and if direct bilirubin is within normal
range, subject may be eligible) or
- Alanine (ALT) or aspartate (AST) aminotransferase > 1.5 x ULN
- Active infection requiring treatment with antibiotics
- History of adrenal insufficiency or hypoaldosteronism
- Myocardial infarction or arterial thrombotic event within 6 months, heart failure of
New York Heart Association class II or higher, uncontrolled angina, severe
uncontrolled ventricular arrhythmia
- External beam radiation therapy within 4 weeks of registration
- Prior history of allergic reactions to G-CSF
- Prior history of allergic reactions to docetaxel and/or to medications formulated with
polysorbate 80
- History of active malignancy; patients with a history of cancer that has been
adequately treated and are free of disease recurrence for 3 years or more are allowed
to participate; patients with non-melanoma skin cancers or carcinoma in situ of the
bladder that have been adequately excised are eligible to participate
- Life expectancy of < 12 months at screening
- Grade >= 2 neuropathy
We found this trial at
356
sites
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-487-7447
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-486-6000
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-678-9000
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Priyank P. Patel
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Channing J. Paller
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
Click here to add this to my saved trials
1300 Anne Street NW
Bemidji, Minnesota 56601
Bemidji, Minnesota 56601
(218) 751-5430
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
Sanford Clinic North-Bemidgi Sanford Health is a voluntary, not-for-profit health care organization. Through its entities,...
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 913-948-5588
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
Bristol, Tennessee 37620
Principal Investigator: Asheesh Shipstone
Phone: 423-578-8538
Click here to add this to my saved trials
Bristol, Virginia 24201
Principal Investigator: Asheesh Shipstone
Phone: 423-578-8538
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Benjamin A. Gartrell
Phone: 718-379-6862
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Benjamin A. Gartrell
Phone: 718-379-6862
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Benjamin A. Gartrell
Phone: 718-379-6862
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
1501 Trousdale Drive
Burlingame, California 94010
Burlingame, California 94010
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Castro Valley, California 94546
Principal Investigator: Ari D. Baron
Phone: 510-537-1234
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
Cheyenne, Wyoming 82001
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
Cincinnati, Ohio 45255
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
Clinton, North Carolina 28328
Principal Investigator: James N. Atkins
Phone: 919-587-9077
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
4050 Coon Rapids Blvd NW
Coon Rapids, Minnesota 55433
Coon Rapids, Minnesota 55433
(763) 236-6000
Principal Investigator: David M. King
Phone: 952-993-1517
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
Click here to add this to my saved trials
Corbin, Kentucky 40701
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
Council Bluffs, Iowa 51503
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
Creston, Iowa 50801
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Creve Coeur, Missouri 63141
Principal Investigator: Joel Picus
Phone: 800-600-3606
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: Priyank P. Patel
Phone: 800-446-5532
Click here to add this to my saved trials
Davis, California 95616
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
Click here to add this to my saved trials
Denver, Colorado 80206
Principal Investigator: Keren Sturtz
Phone: 877-225-5654
Click here to add this to my saved trials
3773 Chry Crk North Dr # 101
Denver, Colorado 80209
Denver, Colorado 80209
Principal Investigator: Keren Sturtz
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
777 Bannock St
Denver, Colorado 80204
Denver, Colorado 80204
(303) 436-6000
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Denver Health Medical Center Denver Health is a comprehensive, integrated organization providing level one care...
Click here to add this to my saved trials
2525 S Downing St
Denver, Colorado 80210
Denver, Colorado 80210
(303) 778-1955
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Porter Adventist Hospital Founded in 1930, Porter Adventist Hospital has provided people throughout Denver and...
Click here to add this to my saved trials
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
Denver, Colorado 80218
720-754-4800
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
Click here to add this to my saved trials
4567 E 9th Ave
Denver, Colorado 80220
Denver, Colorado 80220
(303) 320-2121
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Rose Medical Center Well known as a Denver institution and a 9th Avenue landmark for...
Click here to add this to my saved trials
Des Moines, Iowa 50309
Principal Investigator: Robert J. Behrens
Phone: 515-282-2921
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Robert J. Behrens
Phone: 515-282-2200
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
Des Moines, Iowa 50314
(515) 247-3121
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Mercy Medical Center - Des Moines Mercy Medical Center
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
Des Moines, Iowa 50309
(515) 241-6212
Principal Investigator: Robert J. Behrens
Phone: 515-241-6727
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
Click here to add this to my saved trials
700 E University Ave
Des Moines, Iowa 50316
Des Moines, Iowa 50316
(515) 263-5612
Principal Investigator: Robert J. Behrens
Phone: 515-241-8704
Iowa Lutheran Hospital Iowa Lutheran Hospital has a long history of serving the Des Moines...
Click here to add this to my saved trials
Click here to add this to my saved trials
Durango, Colorado 81301
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
6401 France Ave S
Edina, Minnesota 55435
Edina, Minnesota 55435
(952) 924-5000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Southdale Hospital Fairview Health Services is an award-winning nonprofit health care system based in...
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Priyank P. Patel
Phone: 800-446-5532
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
Englewood, Colorado 80113
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
501 E. Hampden Ave.
Englewood, Colorado 80113
Englewood, Colorado 80113
303-788-5000
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Enumclaw, Washington 98022
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
101 S Major St
Eureka, Illinois 61530
Eureka, Illinois 61530
309-467-2371
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Eureka Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
820 4th St N
Fargo, North Dakota 58102
Fargo, North Dakota 58102
(701) 234-6161
Principal Investigator: Preston D. Steen
Phone: 701-234-6161
Roger Maris Cancer Center Sanford Health is an integrated health system headquartered in the Dakotas...
Click here to add this to my saved trials